The PSA Decision

PSA is the first screening test a man meets that demands a conversation instead of a checkbox — and most men get the checkbox anyway. This page assumes you have met the debate (the PSA topic owns the full argument) and takes the next step: the numbers to hold in your head, the inputs that should tilt the decision either way, and the follow-up contract that makes the test safe to take.

Why This Test Is Not Like the Others

Blood pressure and colorectal screening have settled answers: the benefit is large, the harms are modest, and the question that remains is compliance. PSA is different. Two enormous randomized trials came to different conclusions, the treatment a positive test triggers can permanently change continence and sexual function, and the cancers it finds are a mix of lethal and lazy that no current test can sort perfectly. That is why the US Preventive Services Task Force gives PSA a grade C for men 55–69 — an individualized decision, to be made in conversation — and a grade D for men 70 and older, where the harms outweigh the benefit (2018). The task here is not to resolve the debate. It is to give you the raw materials of your own decision: the numbers, the inputs, and the script.

The Numbers Behind the Conversation

The European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized over 160,000 men aged 55–69 across seven countries. At 9 years, screening cut prostate-cancer mortality by 20% (Schröder et al., NEJM, 2009); at 13 years the reduction held at 21% (Schröder et al., Lancet, 2014). The absolute math from that update: 781 men needed to be invited to screening to prevent one prostate-cancer death, and 27 men needed to be diagnosed with prostate cancer — many of whom were treated for disease that would never have harmed them. The Göteborg arm, which screened younger men (starting at 50) with less contamination, found a 44% reduction at 14 years (Hugosson et al., Lancet Oncology, 2010). The American PLCO trial of over 76,000 men found no significant mortality difference at 7–10 years (Andriole et al., NEJM, 2009) — and still none at 17 years (Pinsky et al., Cancer, 2017) — largely because most men in its control group got PSA testing anyway. The honest synthesis: the benefit is real but smaller and slower than early hopes, the harms are certain, and the decision is genuinely yours to make.

The Decision Inputs

The conversation has structure. Five inputs do most of the work, and each pushes in a direction:

The Baseline-Before-Fifty Idea

There is a middle path between "test everyone yearly" and "never test," and it starts with a single blood draw in the mid-forties. In a large Swedish and American cohort study, men whose baseline PSA sat in the top decile for their age carried most of the later risk of metastatic prostate cancer, while a value below the age-specific median was broadly reassuring for decades (Vickers et al., BMJ, 2013). The logic: one number at 45–49 converts screening from an annual reflex into a risk-stratified schedule — low baselines can space future tests years apart, high baselines earn closer watching. It is an attractive idea, and it is worth noting the honest limits: the strategy is studied in cohorts, not yet validated by a randomized trial, and guidelines differ on whether to recommend a midlife baseline at all. Still, if you are going to test, a baseline beats a surprise — it gives every later number something to be compared against, which is exactly how clinicians read PSA anyway: as a trend, not a verdict.

Running the Conversation, Step by Step

• 📋 Do the homework before the draw. A Cochrane review of decision aids for screening and treatment choices found they consistently improve knowledge and reduce decisional conflict (Stacey et al., 2017). The PSA topic is a reasonable stand-in.
• 🗣️ Ask three questions. What would we do with a high result? What is my personal risk, given family history and ancestry? And what does a biopsy cost me if it turns out negative — in pain, infection risk, and weeks of worry?
• 📄 Say the script. "I've read both sides of the PSA argument. Can we decide together whether testing makes sense for me, at my age and risk?" — that sentence alone converts the checkbox into a conversation.
• 🚦 State your values plainly. If you found a low-grade cancer you could safely watch, would you want to know? There is no right answer — the conversation exists to surface yours.
• ⏰ Time it deliberately. Average risk: open at 50. Family history or Black ancestry: 45. Multiple relatives with early disease: some guidelines say 40.
• 🔁 Revisit, don't re-litigate. The decision is not permanent. As your health and horizon change — a new diagnosis, a milestone birthday — the math changes with it, and a two-minute check-in beats a decade of drift.

The Follow-Up Contract

The most important part of the PSA decision happens before the needle: you decide what happens next. The contract has three clauses. First, a low result means interval testing, not freedom — two to four years apart depending on your baseline and risk, which is how the PSA topic's trend logic works in practice. Second, an elevated result means repeat before react: PSA can spike after infection, recent ejaculation, or even a long bike ride, so a single high value triggers a repeat draw, not an alarm. Third, if the elevation persists, the modern path runs through MRI before biopsy — the PRECISION trial found that an MRI-first strategy detects more clinically significant cancer and fewer insignificant cancers than going straight to biopsy (Kasivisvanathan et al., NEJM, 2018). And if a biopsy does find low-grade disease, the mainstream response is now active surveillance — watching, not operating — which is the middle path the PSA topic documents in detail. A man who knows all three clauses going in is not gambling; he is screening with a plan.

Related Topics